Anti-angiogenic therapy for prostate cancer: rationale and ongoing trialsAuthor(s): Bamidele A Adesunloye, William L Dahut
Prostate cancer is the most commonly diagnosed malignancy and the second leading cause of cancer deaths among men in the USA. Early stages of the disease are curable but once metastasis ensues available treatment options do not lead to durable remissions or cure. Therefore, there is concerted effort to discover therapies that would curtail disease proliferation and prolong survival. Angiogenesis seems to play an important role in the pathophysiology of prostate cancer and many anti-angiogenic agents are currently in different stages of development. The following discussion will highlight the importance of angiogenesis as a target and review the status of some of the anti-angiogenic agents under development.